Healthcare Industry News:  bivalirudin 

Biopharmaceuticals Personnel

 News Release - April 11, 2007

The Medicines Company Elects Hiroaki Shigeta to Board of Directors

PARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) today announced the appointment of Hiroaki Shigeta to the Company's Board of Directors. Mr. Shigeta has a distinguished 40-year career leading international affiliates of global pharmaceutical firms.

Mr. Shigeta served as President and CEO, from 1993 to 2000, of Nippon Roche KK, a wholly-owned Japanese affiliate of Roche Holding of Switzerland, becoming Chairman and Representative Director in 2001. In 2003, he became US Head, Far East Relations of Hoffmann-La Roche, Inc. Earlier on in his career, Mr. Shigeta spent 18 years at Sandoz, leading divisions in Japan, Canada, Brazil, Switzerland and Portugal. In his last position at Sandoz he was in charge of all Sandoz pharma business in Japan as Executive Vice President and member of the Board of Sandoz Yakuhin KK, Tokyo. Mr. Shigeta is also a paid consultant to The Medicines Company.

Clive Meanwell, Chairman and Chief Executive Officer of The Medicines Company, said, "I am pleased to welcome Hiro to the Company's Board. His extensive experience in building and running international business units will be invaluable as we continue to our plans to expand our acute care franchise."

The Medicines Company is committed to delivering innovative, cost-effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is http://www.themedicinescompany.com.

Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates," plans and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's 10-K filed on March 1, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.


Source: The Medicines Company

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.